Aeglea Biotherapeutics
5 clinical trials · Sponsor
◉ Watch Aeglea Biotherapeutics
| Record | Firm | Date |
|---|---|---|
| A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency (NCT05676853) | Aeglea Biotherapeutics | 2023-04-04 |
| A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency (NCT05154890) | Aeglea Biotherapeutics | 2021-05-13 |
| Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency (NCT03921541) | Immedica Pharma AB | 2019-05-01 |
| Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer (NCT03371979) | Aeglea Biotherapeutics | 2017-12-21 |
| A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (NCT03378531) | Aeglea Biotherapeutics | 2017-12-07 |
| A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency (NCT02488044) | Aeglea Biotherapeutics | 2016-06-01 |
Track Aeglea Biotherapeutics automatically
Every clearance here is in the API, with alerts when new ones post.